Zoneddy Dayao

1.5k total citations
26 papers, 400 citations indexed

About

Zoneddy Dayao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Zoneddy Dayao has authored 26 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Zoneddy Dayao's work include Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (5 papers) and Medication Adherence and Compliance (4 papers). Zoneddy Dayao is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), Breast Cancer Treatment Studies (5 papers) and Medication Adherence and Compliance (4 papers). Zoneddy Dayao collaborates with scholars based in United States, Switzerland and United Kingdom. Zoneddy Dayao's co-authors include Melanie Royce, Mark R. Somerfield, Melinda L. Telli, N. Lynn Henry, Ursa Brown‐Glaberman, Tari A. King, Angela DeMichele, Beverly Moy, Ben Ho Park and Nicholas C. Turner and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Nutrients.

In The Last Decade

Zoneddy Dayao

25 papers receiving 397 citations

Peers

Countries citing papers authored by Zoneddy Dayao

Since Specialization

Citations

This map shows the geographic impact of Zoneddy Dayao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zoneddy Dayao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zoneddy Dayao more than expected).

Fields of papers citing papers by Zoneddy Dayao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zoneddy Dayao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zoneddy Dayao. The network helps show where Zoneddy Dayao may publish in the future.

Co-authorship network of co-authors of Zoneddy Dayao

This figure shows the co-authorship network connecting the top 25 collaborators of Zoneddy Dayao. A scholar is included among the top collaborators of Zoneddy Dayao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zoneddy Dayao. Zoneddy Dayao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update 2024 ·Journal of Clinical Oncology ·Rachel A. Freedman, Jennifer L. Caswell‐Jin, Michael J. Hassett, Mark R. Somerfield, Sharon H. Giordano, (unknown), Mariana Chávez‐MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, (unknown), Stephanie L. Graff, Tari A. King, Gary H. Lyman, (unknown), Cheryl Perkins, Melinda L. Telli, Maureen Trudeau, Antonio C. Wolff, (unknown)	18
2	Developing questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study 2024 ·Clinical and Experimental Medicine ·Bernard Tawfik, (unknown), Ursa Brown‐Glaberman, (unknown), M. Lee Van Horn, (unknown), Zoneddy Dayao, V. Shane Pankratz, Andrew L. Sussman, Dolores D. Guest	0
3	A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2 2023 ·Supportive Care in Cancer ·Bernard Tawfik, Zoneddy Dayao, Ursa Brown‐Glaberman, V. Shane Pankratz, Jacqueline M. Lafky, Charles L. Loprinzi, Debra L. Barton	7
4	“Care needs to be integrated” Patient and provider perspectives on a cancer shared-care model 2023 ·Journal of Cancer Survivorship ·(unknown), Miria Kano, Stephanie Rieder, (unknown), Tawny W. Boyce, Teresa Rutledge, Zoneddy Dayao, Andrew L. Sussman	1
5	Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study 2022 ·Frontiers in Oncology ·Miria Kano, (unknown), (unknown), (unknown), Dolores D. Guest, Ellen Burgess, (unknown), V. Shane Pankratz, Teresa Rutledge, Zoneddy Dayao, Larissa Myaskovsky	23
6	Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A 2022 ·JCO Oncology Practice ·Amy S. Clark, Erin F. Cobain, Zoneddy Dayao, Mark R. Somerfield, Angela DeMichele, N. Lynn Henry	3
7	Southwest Harvest for Health: An Adapted Mentored Vegetable Gardening Intervention for Cancer Survivors 2021 ·Nutrients ·Cindy K. Blair, Prajakta Adsul, Dolores D. Guest, Andrew L. Sussman, Linda S. Cook, Elizabeth Harding, (unknown), (unknown), Ellen Burgess, (unknown), Ursa Brown‐Glaberman, (unknown), (unknown), Zoneddy Dayao, V. Shane Pankratz, Sally M. Davis, Wendy Demark‐Wahnefried	11
8	Developing a survivorship care plan (SCP) delivery process for patients and primary care providers serving poor, rural, and minority patients with cancer 2021 ·Supportive Care in Cancer ·Bernard Tawfik, (unknown), (unknown), (unknown), Inigo San Gil, (unknown), Suzanne Gagnon, Miria Kano, (unknown), (unknown), (unknown), Charles L. Wiggins, Andrew L. Sussman, Zoneddy Dayao	7
9	Southwest Harvest for Health: Adapting a mentored vegetable gardening intervention for cancer survivors in the southwest 2021 ·Contemporary Clinical Trials Communications ·Cindy K. Blair, Elizabeth Harding, Prajakta Adsul, (unknown), Dolores D. Guest, (unknown), Andrew L. Sussman, (unknown), Linda S. Cook, (unknown), Zoneddy Dayao, Ursa Brown‐Glaberman, (unknown), V. Shane Pankratz, (unknown), Sally M. Davis, Wendy Demark‐Wahnefried	5
10	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update 2020 ·Journal of Clinical Oncology ·Neelima Denduluri, Mark R. Somerfield, Mariana Chávez‐MacGregor, Amy Comander, Zoneddy Dayao, Andrea Eisen, Rachel A. Freedman, (unknown), Stephanie L. Graff, Michael J. Hassett, Tari A. King, Gary H. Lyman, (unknown), Raquel Nunes, Cheryl Perkins, Melinda L. Telli, Maureen Trudeau, Antonio C. Wolff, Sharon H. Giordano	76
11	Pharmacist-Driven Oral Oncolytic Medication Education and Consent 2020 ·JCO Oncology Practice ·(unknown), Bernard Tawfik, (unknown), Richard C. Lauer, (unknown), Zoneddy Dayao	2
12	Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105. 2019 ·Journal of Clinical Oncology ·Dawn L. Hershman, Joseph M. Unger, (unknown), Anna Moseley, Kathryn B. Arnold, Shaker R. Dakhil, Benjamin Esparaz, (unknown), Mark L. Graham, (unknown), William J. Edenfield, Zoneddy Dayao, Julie R. Gralow, Scott D. Ramsey, Alfred I. Neugut	3
13	The Conundrum of Adjuvant HER2 Treatment Options 2018 ·Frontiers in Oncology ·Ajaz Bulbul, (unknown), Zoneddy Dayao	2
14	Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families 2017 ·Journal of Community Genetics ·(unknown), Harold D. Delaney, Kristina G. Flores, (unknown), Melanie Royce, Zoneddy Dayao, Tuya Pal, Anita Y. Kinney	11
15	Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52 2017 ·Cancer Research ·(unknown), (unknown), Priya Rastogi, CE Geyer, Louis Fehrenbacher, (unknown), Zoneddy Dayao, Rachel Rabinovitch, (unknown), P. Flynn, Luis Báez-Díaz, Soonmyung Paik, SM Swain, EP Mamounas, (unknown), Norman Wolmark	29
16	Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature 2016 ·Journal of Medical Case Reports ·(unknown), Pranshu Bansal, David Lynch, Cristhiam M. Rojas‐Hernandez, Zoneddy Dayao	5
17	HER2-targeted therapy for early-stage breast cancer: a comprehensive review. 2014 ·PubMed ·Ursa Brown‐Glaberman, Zoneddy Dayao, Melanie Royce	20
18	Abstract PD07-01: Z1031B Neoadjuvant Aromatase Inhibitor Trial: A Phase 2 study of Triage to Chemotherapy Based on 2 to 4 week Ki67 level > 10%. 2012 ·Cancer Research ·(unknown), Vera J. Suman, Lisa McCall, Rui Luo, (unknown), Arjen Brink, Mark Watson, Chuang Ma, Gary Unzeitig, (unknown), Pat W. Whitworth, Gildy V. Babiera, Michael Guenther, Zoneddy Dayao, M. Leitch, David M. Ota, John A. Olson, Katie N. Hunt, C Allred	12
19	The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer 2011 ·Breast Cancer Research and Treatment ·(unknown), Zoneddy Dayao, Melanie Royce	6
20	Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case-Control Study in Denmark 2011 ·Breast Diseases A Year Book Quarterly ·(unknown), Zoneddy Dayao	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact